Holen Sie sich die Stockscreener-App
0.599
2.07%
-0.0136
Schlusskurs vom Vortag:
$0.6126
Offen:
$0.6068
24-Stunden-Volumen:
235.82K
Relative Volume:
0.21
Marktkapitalisierung:
$55.16M
Einnahmen:
$11.03M
Nettoeinkommen (Verlust:
$-44.24M
KGV:
-0.9661
EPS:
-0.62
Netto-Cashflow:
$-42.61M
1W Leistung:
-16.59%
1M Leistung:
-14.21%
6M Leistung:
-32.21%
1J Leistung:
-31.05%
1-Tages-Spanne:
$0.5924
$0.6068
1-Wochen-Bereich:
$0.5924
$0.8021
52-Wochen-Spanne:
$0.5837
$1.90
Hyperfine Inc Stock (HYPR) Company Profile
Firmenname
Hyperfine Inc
Sektor
Branche
Telefon
866-796-6767
Adresse
351 NEW WHITFIELD STREET, GUILFORD
Vergleichen Sie HYPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HYPR
Hyperfine Inc
|
0.5999 | 55.16M | 11.03M | -44.24M | -42.61M | -0.62 |
|
ABT
Abbott Laboratories
|
132.49 | 233.05B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.76 | 155.05B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
391.79 | 146.77B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
85.38 | 106.66B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
76.38 | 44.02B | 5.54B | 4.18B | 623.10M | 7.00 |
Hyperfine Inc Stock (HYPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-08-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-05-31 | Eingeleitet | Evercore ISI | Outperform |
| 2022-04-14 | Eingeleitet | Wells Fargo | Overweight |
Hyperfine Inc Aktie (HYPR) Neueste Nachrichten
B. Riley Reduces Price Target for Hyperfine (HYPR) After Sales M - GuruFocus
B. Riley Lowers Price Target on Hyperfine to $1 From $1.20, Keeps Buy Rating - marketscreener.com
Hyperfine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Hyperfine, Inc. (HYPR) Reports Q1 Loss, Lags Revenue Estimates - MSN
Wells Fargo Updates Price Target and Rating for HYPR | HYPR Stoc - GuruFocus
Hyperfine (HYPR) Reports Lower Q1 Revenue, Optimistic About Futu - GuruFocus
Hyperfine, Inc. (NASDAQ:HYPR) Q1 2025 Earnings Call Transcript - Insider Monkey
Hyperfine’s net loss for Q1 2025 hits USD 9.4M - Medical Buyer
Hyperfine outlines 10%–20% revenue growth for 2025 as new product launches and office market entry drive diversification - MSN
Hyperfine Q1 2025 Earnings Call Transcript - MarketBeat
Hyperfine, Inc. Reports Q1 2025 Financial Results - TipRanks
Hyperfine reports Q1 EPS (12c), consensus (12c) - TipRanks
Earnings call transcript: Hyperfine Misses Q1 2025 Revenue Expectations By Investing.com - Investing.com India
Earnings call transcript: Hyperfine Misses Q1 2025 Revenue Expectations - Investing.com
Hyperfine Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Hyperfine Q1 2025 slides reveal portable MRI expansion strategy despite mixed results - Investing.com Australia
Hyperfine Q1 2025 slides reveal portable MRI expansion strategy despite mixed results By Investing.com - Investing.com South Africa
Hyperfine Inc (HYPR) Q1 2025 Earnings: EPS Meets Estimate at -$0 - GuruFocus
Hyperfine Inc Files For Offering Of Up To $50 Million Of Shares Of Class A Common Stock - marketscreener.com
Hyperfine, Inc. SEC 10-Q Report - TradingView
Hyperfine, Inc. Reports First Quarter 2025 Financial Results - The Manila Times
Hyperfine Inc (HYPR) Q1 2025 Earnings Report Preview: What To Lo - GuruFocus
Chipiron building ultra-low portable MRI scanner following $17M raise - BioWorld MedTech
Hyperfine (HYPR) Projected to Post Quarterly Earnings on Tuesday - Defense World
Renaissance Technologies LLC Boosts Stock Holdings in Hyperfine, Inc. (NASDAQ:HYPR) - Defense World
Hyperfine, Inc. to Announce First Quarter 2025 Financial Results on May 13, 2025 - Business Wire
Hyperfine Enrolls Initial Patients in NEURO PMR Study to Evaluate Use of AI-Powered Portable MRI in Neurology Offices - 01net
Hyperfine Enrolls First Patients in Portable MRI Evaluation Study - marketscreener.com
Hyperfine enrolls initial patients in NEURO PMR study - TipRanks
Revolutionary Portable MRI Secures Medicare Coverage as Major Clinical Trial Launches - Stock Titan
Hyperfine (NASDAQ:HYPR) Stock Price Up 0.5% – Should You Buy? - Defense World
HYPR Stock Price and Chart — NASDAQ:HYPR - TradingView
HYPR stock touches 52-week low at $0.76 amid market challenges - Investing.com
Lake Street Initiates Coverage of Hyperfine (HYPR) with Buy Recommendation - MSN
Lake Street starts Hyperfine stock with Buy, sets $1.50 target By Investing.com - Investing.com Australia
Lake Street starts Hyperfine stock with Buy, sets $1.50 target - Investing.com
Lake Street Initiates Hyperfine at Buy With $1.50 Price Target -March 24, 2025 at 08:20 am EDT - MarketScreener
Hyperfine initiated with a Buy at Lake Street - TipRanks
What You Can Learn From Hyperfine, Inc.'s (NASDAQ:HYPR) P/S After Its 28% Share Price Crash - Simply Wall St
Hyperfine price target lowered to $1.20 from $1.50 at B. Riley - TipRanks
B. Riley Trims Price Target on Hyperfine to $1.20 From $1.50, Keeps Buy Rating -March 20, 2025 at 07:57 am EDT - Marketscreener.com
Hyperfine Inc (NASDAQ: HYPR) Fell -6.75%, Now What? Don’t Panic - Stocksregister
Hyperfine, Inc. (NASDAQ:HYPR) Q4 2024 Earnings Call Transcript - Insider Monkey
Hyperfine Inc. Faces Potential Stock Price Decline Amid $150 Million Securities Sale Plan - TipRanks
Hyperfine Inc. Earnings Call: Growth Amid Challenges - TipRanks
Jefferies lifts Hyperfine stock price target to $1.20, keeps Hold rating By Investing.com - Investing.com South Africa
Jefferies lifts Hyperfine stock price target to $1.20, keeps Hold rating - Investing.com
HYPR Stock Jumps on NVIDIA Partnership to Advance AI Neuroimaging - Nasdaq
Hyperfine teams up with NVIDIA to enhance AI-powered portable MR - DOTmed HealthCare Business News
Hyperfine reports net loss of USD 10.39M in Q4 2024 - Medical Buyer
Hyperfine Inc (HYPR) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges By GuruFocus - Investing.com Canada
Finanzdaten der Hyperfine Inc-Aktie (HYPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Hyperfine Inc-Aktie (HYPR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| TEISSEYRE THOMAS | Chief Operating Officer |
Nov 18 '24 |
Sale |
0.85 |
2,800 |
2,380 |
88,227 |
| TEISSEYRE THOMAS | Chief Operating Officer |
Aug 16 '24 |
Sale |
1.05 |
2,746 |
2,883 |
91,027 |
| TEISSEYRE THOMAS | Chief Operating Officer |
May 16 '24 |
Sale |
0.88 |
2,753 |
2,423 |
93,773 |
0.75%
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):